Cost-effectiveness of midostaurin in the treatment of acute myeloid leukemia with the FLT3 mutation in Spain
Arenaza, Ainhoa (Clínico San Carlos Hospital)
Diez, Raúl (Hospital Universitario de Getafe (Madrid))
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona)
Di Nicolantonio, Roberta (Novartis Farmacéutica S.A)
Gostkorzewicz, Joana (Novartis Farmacéutica S.A)
Martínez, Carlos (Arabako Unibertsitate Ospitalea (Vitoria, País Basc))
Martínez Llinàs, Diana (Oblikue Consulting. S.L)
Martínez-López, Joaquín (Hospital 12 de Octubre (Madrid))
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València))
Moure-Fernández, Aída (Oblikue Consulting. S.L)
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau)
Vinent, Joan Lluís (Hospital Sant Joan de Déu (Manresa))
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	The addition of midostaurin to standard chemotherapy (cytarabine and daunorubicin) has shown significant improvements in the survival of patients with acute myeloid leukemia with the FLT3 mutation (FLT3-AML). The objective of this study was to determine whether this intervention would be cost-effective in Spain. A partitioned survival model with five health states was developed (diagnosis and induction, complete remission, no complete remission, transplantation and death). A lifetime time horizon and the Spanish National Health System perspective were adopted. During the first three years, permanence in the different health states was determined according to the results of the RATIFY study. In successive years, the death rates of the Spanish population adjusted by a factor to reflect long-term disease-related mortality were used. Utilities were obtained from the literature. Pharmacological costs (first and second line) and the costs of other health resources (hospitalizations, visits and tests) were included. The robustness of the model was evaluated by deterministic and probabilistic sensitivity analyses. The addition of midostaurin resulted in 1. 46 life years gained (LYG) and 1. 23 quality-adjusted life years (QALY) gained and implied an additional cost of € 47,955, resulting in an incremental cost-effectiveness ratio (ICER) of € 32,854/LYG and an incremental cost-utility ratio of € 38,985/QALY. In the univariate sensitivity analysis, the threshold of € 50,000/QALY was not exceeded in any case; taking into consideration potential discounts of 20-40% in the PVL of midostaurin the ICER would be below € 30,000/QALY, a commonly accepted threshold in Spain. In the probabilistic analysis, when the threshold was € 50,000/QALY, midostaurin was cost-effective in 82. 3% of simulations. According to our modeling, midostaurin, in combination with standard chemotherapy, could be an efficient alternative for the treatment of FLT3-AML in Spain. © 2019 Arenaza et al.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	AML ; Economic evaluation ; Efficiency ; Health economics ; Modeling
Publicado en:	ClinicoEconomics and outcomes research, Vol. 11 (2019) , p. 683-694, ISSN 1178-6981

DOI: 10.2147/CEOR.S222879
PMID: 32009807

12 p, 2.2 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados